Enhanced penetration and anti-psoriatic efficacy of curcumin by improved smartPearls technology with the addition of glycyrrhizic acid

Jin, Nanguo; Lin, Jian‐Sheng; Yang, Caiyun; Wu, Chenyuan; He, Jingwen; Yang, Qian; Chen, Jing; Zheng, Guangmei; Lv, Lingling; Han, Liang; Chen, Jianmin; Ruan, Zonghai

doi:10.1016/j.ijpharm.2020.119101

Cited by 20 publications

(19 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among the preclinical studies, eight were in vivo studies ( Jain et al, 2016 ; Jia and Fang, 2017 ; Mao et al, 2017 ; Sun et al, 2017 ; Qu, 2018 ; Zhang et al, 2019 ; Jin et al, 2020 ; Badanthadka et al, 2021 ), and the treatment of imiquimod (IMQ)-induced psoriasis-like mice comprised oral ( Jia and Fang, 2017 ; Qu, 2018 ) and topical ( Jain et al, 2016 ; Mao et al, 2017 ; Sun et al, 2017 ; Zhang et al, 2019 ; Jin et al, 2020 ; Badanthadka et al, 2021 ) CUR. Four studies ( Jain et al, 2016 ; Jia and Fang, 2017 ; Mao et al, 2017 ; Qu, 2018 ) used BALB/c mice, and four studies ( Sun et al, 2017 ; Zhang et al, 2019 ; Jin et al, 2020 ; Badanthadka et al, 2021 ) used C57BL mice. Two studies ( Jia and Fang, 2017 ; Qu, 2018 ) reported intervention with CUR gavage, and six studies ( Jain et al, 2016 ; Mao et al, 2017 ; Sun et al, 2017 ; Zhang et al, 2019 ; Jin et al, 2020 ; Badanthadka et al, 2021 ) used a topical intervention method.…”

Section: Resultsmentioning

confidence: 99%

“…Four studies ( Jain et al, 2016 ; Jia and Fang, 2017 ; Mao et al, 2017 ; Qu, 2018 ) used BALB/c mice, and four studies ( Sun et al, 2017 ; Zhang et al, 2019 ; Jin et al, 2020 ; Badanthadka et al, 2021 ) used C57BL mice. Two studies ( Jia and Fang, 2017 ; Qu, 2018 ) reported intervention with CUR gavage, and six studies ( Jain et al, 2016 ; Mao et al, 2017 ; Sun et al, 2017 ; Zhang et al, 2019 ; Jin et al, 2020 ; Badanthadka et al, 2021 ) used a topical intervention method. Topical CUR has been formulated into different dosage forms with improved penetration and efficacy, including tacrolimus and CUR co-loading ( Jain et al, 2016 ), CUR-loaded nanoparticles ( Sun et al, 2017 ), CUR-loaded nanoparticles incorporated in silk fibroin hydrogel ( Mao et al, 2017 ), and CUR-loaded hyaluronic acid-modified ethosomes ( Zhang et al, 2019 ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of curcumin in psoriasis: preclinical and clinical evidence and possible mechanisms

et al. 2022

View full text Add to dashboard Cite

Background: Psoriasis is a chronic and immune-mediated inflammatory skin disease. Many studies have shown that curcumin (CUR) has strong anti-inflammatory effects and can improve psoriasis; however, its efficacy and safety have not been confirmed, and the specific mechanism remains to be elucidated.Objective: To evaluate the efficacy, safety, and possible mechanisms of CUR in the treatment of psoriasis.Methods: The Cochrane Library, Embase, PubMed, Web of Science, China National Knowledge Infrastructure, Wanfang, and VIP (China Science and Technology Journal Database) were systematically searched for clinical trials and preclinical studies on the use of CUR in psoriasis treatment. All databases were searched from inception to January 2022. The meta-analysis was performed using RevMan 5.3 software.Results: Our meta-analysis included 26 studies, comprising seven clinical randomized controlled trials and 19 preclinical studies. A meta-analysis of clinical trials showed that both CUR monotherapy and combination therapy improved Psoriasis Area and Severity Index (PASI) scores in patients compared to controls (standard mean difference [std.MD]: −0.83%; 95% confidence interval [CI]: −1.53 to 0.14; p = 0.02). In preclinical studies, CUR showed better performance in improving the phenotype of psoriatic dermatitis mice compared to controls, including total PASI score (std.MD: 6.50%; 95% CI: 10.10 to −2.90; p = 0.0004); ear thickness (p = 0.01); and the expression of inflammatory cytokines such as interleukin (IL)-17, tumor necrosis factor (TNF)-α, IL-17F, and IL-22 (p < 0.05). In cell studies, CUR inhibited cell proliferation (p = 0.04) and the cell cycle (p = 0.03) and downregulated the inflammatory cytokines IL-6 and IL-8 (p < 0.05).Conclusions: CUR has excellent efficacy and broad potential to treat psoriasis in multiple ways. Its use also plays a crucial role in improving the psoriasis phenotype and reducing the inflammatory microenvironment. In conclusion, our findings suggest that CUR alone or in combination with other conventional treatments can effectively treat psoriasis.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Efficacy and safety of curcumin in psoriasis: preclinical and clinical evidence and possible mechanisms

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Previous in vitro and in vivo studies have reported the anti-psoriatic properties of Curcumin via suppression of pro-inflammatory cytokines, down-regulation of NF-kB and MAPK signaling pathways and upregulation of involucrin and filaggrin, proteins that regulate skin barrier function [66][67][68]. In addition, several formulations aimed to enhance bioavailability, solubility and physicochemical properties of Curcumin have been evaluated in different animal models of psoriasis, demonstrating an improvement of its anti-psoriatic effect [69][70][71]. In the present study, we demonstrated for the first time the anti-inflammatory properties of CurEpiβCD-Gel in an in vitro model of psoriasis, established using HaCaT keratinocytes treated with TNF-α.…”

Section: Discussionmentioning

confidence: 99%

Preparation, Characterization and Evaluation of the Anti-Inflammatory Activity of Epichlorohydrin-β-Cyclodextrin/Curcumin Binary Systems Embedded in a Pluronic®/Hyaluronate Hydrogel

Fernández-Romero

Maestrelli

García-Gil

et al. 2021

IJMS

View full text Add to dashboard Cite

Curcumin (Cur) is an anti-inflammatory polyphenol that can be complexed with polymeric cyclodextrin (CD) to improve solubility and bioavailability. The aim of the present work was to prepare a CurCD hydrogel to treat inflammatory skin conditions. Epichlorohydrin-β-CD (EpiβCD) was used as polymeric CD. To characterize the binary system, solid-state and in-solution studies were performed. Afterwards, an experimental design was performed to optimize the hydrogel system. Finally, the CurEpiβCD hydrogel system was tested for anti-inflammatory activity using a HaCat psoriasis cell model. Co-grinded Cur/EpiβCD binary system showed a strong interaction and Curcumin solubility was much improved. Its combination with Pluronic® F-127/hyaluronate hydrogel demonstrated an improvement in release rate and Curcumin permeation. After testing its anti-inflammatory activity, the system showed a significant reduction in IL-6 levels. Hydrogel-containing CurEpiβCD complex is a great alternative to treat topical inflammatory diseases.

show abstract

“…Глицерризиновая кислота, пентациклический тритерпеноид, активный компонент корня солодки и пиперин, алкалоид черного перца, наряду с присущей данным соединениям собственной биологической активностью, способны повышать биодоступность куркумина, катехинов и других полифенолов при их совместном применении. Глицерризиновая кислота обладает антиоксидантными, противовоспалительными, противоаллергическими свойствами, усиливает иммуномодулирующие, противовирусные, противовоспалительные, антиоксидантные, антитоксические и гепатопротекторные свойства куркумина [23]. Пиперин, наряду с антиоксидантными, антитоксическими, противоопухолевыми свойствами, не только увеличивает биодоступность куркумина, ингибируя его глюкуронирование и увеличивая транспортирование в плазму, способствуя таким образом увеличению его биодоступности, но и повышает антиканцерогенные свойства данного куркуминоида [12,27].…”

Section: Discussionunclassified

Corrective effects of original bioflavonoid complex in the cyclophosphamide-induced immunity disorders

et al. 2021

View full text Add to dashboard Cite

Our aim was to evaluate immunomodulatory properties of an original bioflavonoid complex in experimental immune disturbances induced by cyclophosphamide (Cy). We have studied morphometric indexes of thymus and spleen, as well as blood leukocyte counts, cell proliferative activity in lymphoid organs, delayed hypersensitivity responses to T cell-dependent antigen, along with differentiation activity of bone marrow stem cells in experimental animals during Cy-induced immune suppression after a course of bioflavonoid treatment. Suspension of the bioflafonoid complex was introduced to the male mice (СВАхC57Bl/6)F1 aged 12- 14 weeks at a daily dose of 2 mg/animal (80 mg/kg), per os, using gastric catheter, over 14 days. Cytostatic immunosuppression was produced by a single intraperitoneal Cy injection. Proliferative activity of spleen and thymic cells was determined by standard method with Н3 -thymidine incorporation in the 72-h cell culture. Cellular immune response was assayed by the degree of delayed-type hypersensitivity development in response to sheep erythrocytes. The number of hematopoietic progenitors was evaluated by culturing bone marrow cells in methylcellulose-based medium. The experiments have shown mitigation of immunosuppressive effects induced by Cy, in the course of bioflavonoid complex treatment, with respect to absolute and relative mass of lymphoid organs and leukocyte numbers in peripheral blood. Moreover, we have demonstrated decreased effects of Cy treatment upon the spontaneous activity of spleen cells, mitogen-induced thymocyte and splenocyte proliferation, intensivity of delayed-type hypersensitivity response that reached the values of intact animals. Following the course of bioflavonoids, we have revealed an increase in early hematopoietic progenitors. Alleviation of Cy-induced suppressive effects upon cellular immune response, proliferation rates of immune cells, as well as stimulation of hematopoietic stem cell functions suggest a sufficient capacity of the original bioflavonoid complex for modulation of immunity and hematopoiesis, thus presenting experimental proofs for its potential usage as an adjuvant treatment of the patients with malignant diseases.

show abstract

Enhanced penetration and anti-psoriatic efficacy of curcumin by improved smartPearls technology with the addition of glycyrrhizic acid

Cited by 20 publications

References 28 publications

Efficacy and safety of curcumin in psoriasis: preclinical and clinical evidence and possible mechanisms

Efficacy and safety of curcumin in psoriasis: preclinical and clinical evidence and possible mechanisms

Preparation, Characterization and Evaluation of the Anti-Inflammatory Activity of Epichlorohydrin-β-Cyclodextrin/Curcumin Binary Systems Embedded in a Pluronic®/Hyaluronate Hydrogel

Corrective effects of original bioflavonoid complex in the cyclophosphamide-induced immunity disorders

Contact Info

Product

Resources

About